BioLineRx Ltd. BLRX

BLRX Company Overview

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and rare diseases. The company operates primarily in the biotechnology and pharmaceutical industries, with a strategic emphasis on treatments that address unmet medical needs through novel mechanisms of action. BioLineRx’s core value proposition has centered on advancing drug candidates through clinical development and leveraging partnerships with larger pharmaceutical companies for commercialization and geographic expansion.

The company’s principal product and revenue driver has been aphexda (motixafortide), a stem-cell mobilization therapy developed for use in autologous stem-cell transplantation in multiple myeloma patients. BioLineRx has also historically maintained an oncology-focused pipeline involving immuno-oncology and tumor microenvironment targets. Founded in Israel in 2003, the company evolved from an early-stage drug development platform into a focused oncology biotechnology company listed on both the Nasdaq and Tel Aviv Stock Exchange. Its strategy has relied on combining internal development capabilities with external licensing, collaborative research, and commercialization partnerships.